Skip to main content

Leapfrog Bio

Monday, February 26, 2024
Leapfrog Bio is a seed stage company focused on developing precision therapeutics targeting solid tumors caused by loss of function mutations. Since inception in 2019 the company has developed and validated a novel pharmacogenomic platform that utilizes the biology of synthetic lethality to screen clinical stage assets. To date the company has discovered 12 novel synthetically lethal drug and sensitizing mutation combinations and filed IP around 4 of these discovers. The company has identified two lead molecules to advance into clinical development in 2024. The company is currently raising a series A round to fund its lead program moving into phase 2a clinical trials in 3 solid tumor types in late 2024. Additionally the company will advance a second program to phase 2 ready and build a deep preclinical pipeline from the series A raise.
Greg Vontz, CEO - Leapfrog Bio




United States


CEO/Top Company Official

Greg Vontz

Lead Product in Development

Undisclosed precision oncology therapeutic entering phase 2a in solid tumors for lung, colon and bladder cancers

Development Phase of Primary Product

Phase II

Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.